StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Travere Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $22.91M. For fiscal 2026 it was -$2.08M. The highest annual figure on record is -$2.08M in fiscal 2026.

Annual ebitda

PeriodPeriod endValueChange
FY2026Dec 31, 2025-$2.08M–
FY2025Dec 31, 2024-$280.27M–
FY2024Dec 31, 2023-$349.61M–
FY2023Dec 31, 2022-$299.09M–
FY2022Dec 31, 2021-$186.68M–
FY2021Dec 31, 2020-$151.58M–
FY2020Dec 31, 2019-$116.95M–
FY2019Dec 31, 2018-$61.37M–
FY2018Dec 31, 2017-$35.99M–
FY2017Dec 31, 2016-$42.08M–
FY2016Dec 31, 2015-$37.36M–
FY2015Dec 31, 2014-$74.41M–
FY2014Dec 31, 2013-$24.56M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2027Jun 30, 2026$8.19M+499.4%
Q1 FY2027Mar 31, 2026-$11.70M–
Q4 FY2026Dec 31, 2025-$14.29M–
Q3 FY2026Sep 30, 2025$40.72M–
Q2 FY2026Jun 30, 2025$1.37M–
Q1 FY2026Mar 31, 2025-$29.87M–
Q4 FY2025Dec 31, 2024-$48.65M–
Q3 FY2025Sep 30, 2024-$44.91M–
Q2 FY2025Jun 30, 2024-$57.36M–
Q1 FY2025Mar 31, 2024-$129.36M–
Q4 FY2024Dec 31, 2023-$84.75M–
Q3 FY2024Sep 30, 2023-$81.11M–
Q2 FY2024Jun 30, 2023-$93.00M–
Q1 FY2024Mar 31, 2023-$90.75M–
Q4 FY2023Dec 31, 2022-$80.39M–
Q3 FY2023Sep 30, 2022-$83.40M–
Q2 FY2023Jun 30, 2022-$70.42M–
Q1 FY2023Mar 31, 2022-$64.89M–
Q4 FY2022Dec 31, 2021-$92.67M–
Q3 FY2022Sep 30, 2021-$23.84M–
Q2 FY2022Jun 30, 2021-$28.70M–
Q1 FY2022Mar 31, 2021-$41.48M–
Q4 FY2021Dec 31, 2020-$111.92M–
Q3 FY2021Sep 30, 2020-$13.00M–
Q2 FY2021Jun 30, 2020-$17.26M–
Q1 FY2021Mar 31, 2020-$9.41M–
Q4 FY2020Dec 31, 2019-$22.88M–
Q3 FY2020Sep 30, 2019-$29.06M–
Q2 FY2020Jun 30, 2019-$31.69M–
Q1 FY2020Mar 31, 2019-$33.33M–
Q4 FY2019Dec 31, 2018-$106.00K–
Q3 FY2019Sep 30, 2018-$30.79M–
Q2 FY2019Jun 30, 2018-$16.92M–
Q1 FY2019Mar 31, 2018-$13.56M–
Q4 FY2018Dec 31, 2017-$10.71M–
Q3 FY2018Sep 30, 2017-$5.99M–
Q2 FY2018Jun 30, 2017-$9.16M–
Q1 FY2018Mar 31, 2017-$10.12M–
Q4 FY2017Dec 31, 2016-$14.04M–
Q3 FY2017Sep 30, 2016-$16.28M–

More Travere Therapeutics figures

See a number that looks wrong?